Dialog Box

Loading...
24 June 2020

EHA 2020 Congress - Classical Hodgkin Lymphoma

KEYNOTE 204 study – relapsed or refractory classical Hodgkin lymphoma
European Hematology Association (EHA) congress

Dr Robin Gasiorowski, Consultant Haematologist, Concord Hospital, Sydney

Dr Robin Gasiorowski from Concord Hospital spoke to Donna Gairns, National Nurse Director, Lymphoma Australia, about a study that was presented during the recent European Hematology Association (EHA) congress, held during 11-21 June 2020. This is the annual congress haematology meeting held each June across Europe, and is attended by Australian and international experts each year. This year the meeting was held as a virtual event due to COVID-19 restrictions.

Dr Robin Gasiorowski is one of the leading investigators in Australia for the international clinical trial that has been named KEYNOTE 204. It is a randomised phase 3 trial that compared the overall outcomes and the side effect profile of two therapies that are currently approved in the relapsed or refractory classical Hodgkin lymphoma group: pembrolizumab and brentuximab vedotin.

The results found that the patients both responded significantly better, but also found that the side effects were less in the group who received pembrolizumab compared to the group who received brentuximab vedotin.

Through this study, it shows that pembrolizumab is the preferred new standard of care for patients with relapsed or refractory classical Hodgkin lymphoma.

Dr Gasiorowski also discussed the study that looked at PET negative early-stage unfavourable Hodgkin lymphoma who had good results when they received higher dose chemotherapy regimen for less cycles, that omitted the need for radiotherapy to consolidate after treatment. This is good for young patients who receive less toxic therapy and experience less late effects from treatment. This will provide clinicians with more information to best inform treatment.

 

EHA25 PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PEMBROLIZUMAB (PEMBRO) VERSUS BRENTUXIMAB VEDOTIN (BV) FOR TREATMENT OF RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)

EHA25 POSITRON EMISSION TOMOGRAPHY GUIDED OMISSION OF RADIOTHERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE III HD17 TRIAL BY THE GHSG

  • Conclusion: PET4-negativity after treatment with “2+2” chemotherapy in patients with newly diagnosed early-stage

 

MORE ABOUT THE KEYNOTE-204 STUDY 

KEYNOTE-204: Randomized, Open-Label, Phase 3 Study of Pembrolizumab Versus Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma.

The KEYNOTE-204 phase 3 study of pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma was presented at the European Hematology Association (EHA) annual congress in June 2020.  It was presented by one of the lead investigators, Prof Luigi Zinzani.  (Abstract LB2600)

https://library.ehaweb.org/eha/2020/eha25th/303389/pier.luigi.zinzani.phase.3.randomized.open-label.study.of.pembrolizumab.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dkeynote-204

Background  

Pembrolizumab is a PD-1 inhibitor used for relapsed or refractory classical Hodgkin lymphoma. It is currently funded in Australia for those who have relapsed (comes back) or refractory (does not respond to treatment). This is for patients who have received an autologous stem cell transplant (auto-SCT) or are found to be unsuitable for an auto-SCT.

Brentuximab vedotin is a drug conjugate (an immunotherapy and chemotherapy combined) that is used to treat classical Hodgkin lymphoma in the relapsed or refractory setting. This is funded in Australia if a patient has relapsed after auto-SCT or are found to be unsuitable for an auto-SCT.

KEYNOTE-204 was a randomised, international, open-label, phase III trial that looked at the outcomes of either using pembrolizumab (pembro) or brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma subtypes, as a single agent (monotherapy).

KEYNOTE-204 updates

All suitable patients (300 in total) were either post an autologous stem cell transplant or were unsuitable for auto-SCT and had either relapsed or had refractory disease. The primary end point (the goal) of the trial was to see the progression free survival (PFS) or the length of time during and after the treatment before the disease progresses.
Roughly half of the patients who took part in the study were given pembro and the other half were given BV. Patients were followed up for a median (average) time of 24.7 months, the median progression, the PFS was 13.2 months with pembro versus 8.3 months with BV. This means that there is a 35% less risk of progression or death when using pembro compared to BV.
These results included those who had not had an auto-SCT, primary refractory disease, prior BV exposure and no exposure to BV. The adverse side effects of both of these drugs were the same as previously experienced when these therapies were used. Where patients had less overall grade 3-5 (more severe) side using pembro compared to using BV.

Conclusion

The results concluded that pembrolizumab should be the preferred treatment of choice or considered as the new standard of care for those with relapsed or refractory classical Hodgkin lymphoma, post auto-SCT or unsuitable for auto-SCT. The patients who received pembro showed better outcomes both with PFS and overall adverse side effects across all subgroups of patients.

For more information 

For more information, please see the Lymphoma Australia interviews by Dr Robin Gasiorowski, Concord Hospital (Sydney) and Dr Michael Dickinson, Peter MacCallum Cancer Centre (Melbourne) who were both investigators on the study in Australia.

YouTube playlist

Category: Research
Tags: classical hodgkin lymphoma hodgkin EHA trials treatment studies study results relapsed hodgkin refractory hodgkin,